Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JESSICA BAUMAN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1619139235
CMS profile
579955
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$13,235.53

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $12,825.00 3
Food and Beverage $410.53 2

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
EMD Serono, Inc. $12,825.00 3
AVEO Pharmaceuticals, Inc. $238.18 1
Merck Sharp & Dohme LLC $172.35 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JESSICA BAUMAN

NPI 1619139235 · CMS profile ID 579955

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619139235?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JESSICA BAUMAN, NPI 1619139235, CMS profile ID 579955. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619139235?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JESSICA BAUMAN, NPI 1619139235, CMS profile ID 579955. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619139235?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JESSICA BAUMAN, NPI 1619139235, CMS profile ID 579955, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1619139235?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $13,235.53 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EMD Serono, Inc. $3,800.0011/27/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052754767 CMS
EMD Serono, Inc. $3,800.0008/18/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052754785 CMS
EMD Serono, Inc. $5,225.0007/11/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052754901 CMS
Merck Sharp & Dohme LLC $172.3506/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048277779 CMS
AVEO Pharmaceuticals, Inc. $238.1806/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049060461 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,346.90 6
PY2021 $6,402.50 6
PY2022 $2,520.00 1
PY2023 $13,235.53 5
PY2024 $3,945.00 3
PY2025 $4,182.50 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $662,530.20 43
PY2024 Recipient $4,600.00 2
PY2024 Principal investigator $597,434.60 56
PY2023 Recipient $3,200.00 1
PY2023 Principal investigator $615,260.38 77
PY2022 Principal investigator $513,473.56 47
PY2021 Principal investigator $536,056.62 88
PY2020 Recipient $3,200.00 1
PY2020 Principal investigator $550,482.65 74
PY2019 Principal investigator $501,598.41 22

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

47 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,551.31 12/31/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH D/B/A
a phase two study assessing the efficacy of osimertinib in combination with savolitinib in patients with EGFRmPPlus and metPlus,locally advanced or metastatic non small cell lung cancer who have progressed following treatment with osimertinib No dispute reported 06/30/2026 914593283
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,698.31 12/31/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH D/B/A
A Phase 3 Randomized Double-blind Multicenter Global Study of Monalizumab or Placebo in Combination with Cetuximab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated with an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 914594025
Principal investigator 1 Merck Sharp & Dohme LLC $15,522.93 12/31/2022 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 940391381
Principal investigator 1 Merck Sharp & Dohme LLC $42,708.60 12/31/2022 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 940391383
Principal investigator 1 Merck Sharp & Dohme LLC $5,813.76 12/31/2022 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 940391385
Principal investigator 1 Merck Sharp & Dohme LLC $1,496.67 12/31/2022 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase III Randomized Trial of MK-3475 Versus Standard Treatment in Subjects with recurrent or metastatic head and neck cancer No dispute reported 06/30/2026 940404989
Principal investigator 1 Merck Sharp & Dohme LLC $9,402.23 12/31/2022 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma R,M cSCC No dispute reported 06/30/2026 940407621
Principal investigator 1 Merck Sharp & Dohme LLC $8,530.48 12/31/2022 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma R,M cSCC No dispute reported 06/30/2026 940407623
Principal investigator 1 Merck Sharp & Dohme LLC $5,860.15 12/31/2022 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 940408607
Principal investigator 1 Merck Sharp & Dohme LLC $39,762.90 12/31/2022 Non-covered Recipient Entity
FOX CHASE CANCER CENTER HEMATOLOGY ONCOLOGY
A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation MK-7684A Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer KEYVIBE-003 No dispute reported 06/30/2026 940419881
Principal investigator 1 EMD Serono, Inc. $2,000.00 12/08/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy Definitive Chemoradiotherapy (TrilynX) No dispute reported 06/30/2026 951099679
Principal investigator 1 Merck Sharp & Dohme LLC $41,683.20 12/02/2022 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent,metastatic head and neck squamous cell carcinoma R,M HNSCC that have progressed after platinum therapy and immunotherapy PD-1,PD-L1 inhibitors LEAP-009 No dispute reported 06/30/2026 940391245
Principal investigator 1 GlaxoSmithKline, LLC. $849.02 11/21/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 943963123
Principal investigator 1 Merck Sharp & Dohme LLC $5,150.00 10/24/2022 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 940407745
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,158.75 10/07/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED PHASE 3 MULTICENTER OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF TAK-788 AS FIRST-LINE TREATMENT VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS No dispute reported 06/30/2026 937175477
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 10/07/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED PHASE 3 MULTICENTER OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF TAK-788 AS FIRST-LINE TREATMENT VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS No dispute reported 06/30/2026 937175479
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,430.00 10/07/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED PHASE 3 MULTICENTER OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF TAK-788 AS FIRST-LINE TREATMENT VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS No dispute reported 06/30/2026 937175481
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,402.00 09/26/2022 Covered Recipient Teaching Hospital
American Oncologic Hospial
Phase I II FIH ICOS Monotherapy Ipi Combination No dispute reported 06/30/2026 933190645
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,250.00 09/23/2022 Non-covered Recipient Entity
Fox Chase Cancer Center-parent Account
Phase I II FIH ICOS Monotherapy Ipi Combination No dispute reported 06/30/2026 933190647
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,050.00 09/14/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED PHASE 3 MULTICENTER OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF TAK-788 AS FIRST-LINE TREATMENT VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS No dispute reported 06/30/2026 937173977
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,670.00 09/14/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED PHASE 3 MULTICENTER OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF TAK-788 AS FIRST-LINE TREATMENT VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS No dispute reported 06/30/2026 937173981
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,500.00 09/14/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED PHASE 3 MULTICENTER OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF TAK-788 AS FIRST-LINE TREATMENT VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS No dispute reported 06/30/2026 937173983
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 09/14/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED PHASE 3 MULTICENTER OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF TAK-788 AS FIRST-LINE TREATMENT VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS No dispute reported 06/30/2026 937173985
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 09/07/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED PHASE 3 MULTICENTER OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF TAK-788 AS FIRST-LINE TREATMENT VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS No dispute reported 06/30/2026 937173427
Principal investigator 1 GlaxoSmithKline, LLC. $268.00 08/16/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 943963121
Principal investigator 1 GlaxoSmithKline, LLC. $3,417.00 08/16/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 943963127
Principal investigator 1 GlaxoSmithKline, LLC. $2,103.80 08/16/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 943963135
Principal investigator 1 PFIZER INC. $6,630.00 08/13/2022 Non-covered Recipient Entity
Institute for Cancer Research
A PHASE 1B 12WEEK OPENLABEL STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS FOLLOWING REPEATED SUBCUTANEOUS ADMINISTRATIONS OF PF06946860 IN PATIENTS WITH CANCER AND CACHEXIA No dispute reported 06/30/2026 949804237
Principal investigator 1 GlaxoSmithKline, LLC. $2,103.80 07/19/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 943963125
Principal investigator 1 GlaxoSmithKline, LLC. $2,438.80 07/19/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 943963133
Principal investigator 1 GlaxoSmithKline, LLC. $2,438.80 07/19/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 943963137
Principal investigator 1 GlaxoSmithKline, LLC. $502.50 07/19/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 943963139
Principal investigator 1 GlaxoSmithKline, LLC. $379.22 07/19/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 943963141
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,590.00 07/06/2022 Non-covered Recipient Entity
Institute For Cancer Research Dba Fox Chase Cancer Center
Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy No dispute reported 06/30/2026 933188753
Principal investigator 1 GlaxoSmithKline, LLC. $3,578.20 06/07/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 943963129
Principal investigator 1 PFIZER INC. $5,015.00 05/27/2022 Non-covered Recipient Entity
The Institute for Cancer Research ICR Depository
A 6WEEK RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO ASSESS THE EFFECT OF REPEATED SUBCUTANEOUS ADMINISTRATION OF PF06946860 ON APPETITE IN PARTICIPANTS WITH ADVANCED CANCER AND ANOREXIA FOLLOWED BY AN 18WEEK OPENLABEL TREATMENT PERIOD No dispute reported 06/30/2026 949745115
Principal investigator 1 EMD Serono, Inc. $21,550.00 04/14/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy & Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of Head & Neck No dispute reported 06/30/2026 951095859
Principal investigator 1 EMD Serono, Inc. $2,000.00 04/14/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy & Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of Head & Neck No dispute reported 06/30/2026 951095863
Principal investigator 1 EMD Serono, Inc. $750.00 04/14/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy & Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of Head & Neck No dispute reported 06/30/2026 951095877
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 04/11/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 943963131
Principal investigator 1 PFIZER INC. $28,625.00 04/01/2022 Non-covered Recipient Entity
The Institute for Cancer Research ICR Depository
A 6WEEK RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO ASSESS THE EFFECT OF REPEATED SUBCUTANEOUS ADMINISTRATION OF PF06946860 ON APPETITE IN PARTICIPANTS WITH ADVANCED CANCER AND ANOREXIA FOLLOWED BY AN 18WEEK OPENLABEL TREATMENT PERIOD No dispute reported 06/30/2026 949822549
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,902.47 03/25/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH D/B/A
a phase two study assessing the efficacy of osimertinib in combination with savolitinib in patients with EGFRmPPlus and metPlus,locally advanced or metastatic non small cell lung cancer who have progressed following treatment with osimertinib No dispute reported 06/30/2026 914598461
Principal investigator 1 GlaxoSmithKline, LLC. $6,408.68 03/24/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II/III STUDY OF GSK3359609 No dispute reported 06/30/2026 943963143
Principal investigator 1 Amgen Inc. $188.00 03/23/2022 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
AMG 510 Expanded access ex EU (w/LTFU) No dispute reported 06/30/2026 942840399
Principal investigator 1 AstraZeneca Pharmaceuticals LP $171,593.98 02/11/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH D/B/A
A Phase 3 Randomized Double-blind Multicenter Global Study of Monalizumab or Placebo in Combination with Cetuximab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated with an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 914597903
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 01/19/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED PHASE 3 MULTICENTER OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF TAK-788 AS FIRST-LINE TREATMENT VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS No dispute reported 06/30/2026 937161983
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 01/14/2022 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A RANDOMIZED PHASE 3 MULTICENTER OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF TAK-788 AS FIRST-LINE TREATMENT VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS No dispute reported 06/30/2026 937161763